Across TCGA pan-cancer cohorts, SLC22A5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC22A5 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SLC22A5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC22A5 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

CCRCC, HNSC, and GBM are the cancer types where SLC22A5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.198	0.887	.024	13	view →
HNSC	OS	Median	IV	0.518	0.867	.009	11	view →
GBM	OS	Tertile	All	0.569	0.309	.008	6	view →
LUAD	DFS	Median	II,III,IV	0.655	0.985	.016	5	view →
LSCC	DFS	Tertile	III,IV	1.000	0.321	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SLC22A5 tumor-vs-normal RNA expression · all SLC22A5 data types